Multiple myeloma classification: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 67: | Line 67: | ||
Multiple myeloma can be classified according to risk status. The risk stratification for multiple myeloma consists of three groups, as follows:<ref name="pmid27291302">{{cite journal| author=Rajkumar SV| title=Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. | journal=Am J Hematol | year= 2016 | volume= 91 | issue= 7 | pages= 719-34 | pmid=27291302 | doi=10.1002/ajh.24402 | pmc=5291298 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27291302 }} </ref> | Multiple myeloma can be classified according to risk status. The risk stratification for multiple myeloma consists of three groups, as follows:<ref name="pmid27291302">{{cite journal| author=Rajkumar SV| title=Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. | journal=Am J Hematol | year= 2016 | volume= 91 | issue= 7 | pages= 719-34 | pmid=27291302 | doi=10.1002/ajh.24402 | pmc=5291298 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27291302 }} </ref><ref name="pmid27002115">{{cite journal| author=Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al.| title=Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. | journal=Blood | year= 2016 | volume= 127 | issue= 24 | pages= 2955-62 | pmid=27002115 | doi=10.1182/blood-2016-01-631200 | pmc=4920674 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27002115 }} </ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | ||
|valign=top| | |valign=top| | ||
| Line 88: | Line 88: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*t(4;14) | *t(4;14) | ||
*Gain( | *Gain(1q21) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
10% | 10% | ||
| Line 98: | Line 98: | ||
*t(14;20) | *t(14;20) | ||
*del(17p) | *del(17p) | ||
*Non-hyperdiploidy | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
15%|- | 15%|- | ||
Revision as of 04:31, 24 July 2018
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma classification On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma classification |
|
Risk calculators and risk factors for Multiple myeloma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2] Shyam Patel [3]
Overview
Multiple myeloma can be classified into several subtypes based on the extent of organ involvement (medullary or extramedullary) and the disease clinical presentation (active symptomatic or smoldering asymptomatic).[1]
Classification
Plasma cell disorders such as multiple myeloma and its related diseases are classified according to disease burden and the extent of organ involvement, as follows:
| Disease | Diagnostic Criteria | Management Approach |
|---|---|---|
plus
plus
|
||
plus
|
Monitoring of complete blood count every 6-12 months | |
plus
|
| |
plus
|
(Please see Therapy section for details |
Multiple myeloma can be classified according to risk status. The risk stratification for multiple myeloma consists of three groups, as follows:[3][4]
| Risk group | Chromosomal Abnormalities | Frequency |
|---|---|---|
|
Standard risk |
|
75% |
|
Intermediate Risk |
|
10% |
|
High risk |
|
15%|- |
References
- ↑ Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B; et al. (1999). "Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts". Cancer. 85 (11): 2305–14. PMID 10357398.
- ↑ 2.0 2.1 2.2 Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY; et al. (2018). "Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel". J Hematol Oncol. 11 (1): 10. doi:10.1186/s13045-017-0549-1. PMC 5771205. PMID 29338789.
- ↑ Rajkumar SV (2016). "Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management". Am J Hematol. 91 (7): 719–34. doi:10.1002/ajh.24402. PMC 5291298. PMID 27291302.
- ↑ Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC; et al. (2016). "Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group". Blood. 127 (24): 2955–62. doi:10.1182/blood-2016-01-631200. PMC 4920674. PMID 27002115.